Should I buy Medpace (MEDP) stock or is it too late?

Medpace · Health Care · price $610

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Truist Securities — 65% of its targets hit on this sector (110 calls tested). It aims for $609 (-0.1 %), call made on July 25, 2026, maturing on July 25, 2027 (81 d ago).

The 6 reliable analysts $649+6.3 %

The 3 other firms $600-1.6 %

How to read it: the 6 reliable firms are not filtered by optimism — 4 aim above the price, 2 below, hence their $649 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Medpace

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Baird	50 %	-10.5 %	8	$624 +2%
UBS	20 %	-26.5 %	5	$673 +10%
William Blair	100 %	+35.2 %	5	—
Credit Suisse	70 %	+31.3 %	10	—

In short — Should you invest in Medpace? Is it too late, still worth it? Analysts are split (22% buy, median target $624, i.e. +2%), and the most reliable on MEDP targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on MEDP, Mizuho (67% hit rate, 3 scored calls), targets $700 (call made on October 7, 2026, maturing on October 7, 2027) (+15%) in its most recent call, and $575 (call made on October 17, 2025, maturing on October 17, 2026) (-6%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 9 ratings, 7 are neutral.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on MEDP

Median target $624 (+2%) · 9 ratings · Hold consensus

Strong Buy00%

Buy222%

Hold778%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Medpace now?

We won't decide for you. The facts: 22% of analysts rate it a buy, median target $624 (+2%), and Mizuho (most reliable on MEDP, 67%) targets $700. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Medpace?

The stated upside is small: the median target ($624) sits just +2% from the price ($610) (most reliable on MEDP: Mizuho, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Medpace still worth investing in?

It depends on the gap between the price ($610) and its estimated value: analysts target $624 on median (+2%), with 22% buys (most reliable on MEDP: Mizuho, 67%). Cross-check with their real reliability on MEDP and the cautions above. Information, not advice.

What's the main risk in buying MEDP?

The consensus is not unanimous: of 9 ratings, 7 are neutral.

→ Go deeper: the full Medpace profile (consensus, analyst reliability, price target, performance).